Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14XZH | ISIN: FR0012882389 | Ticker-Symbol: PHF
Stuttgart
21.11.24
14:46 Uhr
40,500 Euro
-1,000
-2,41 %
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
EQUASENS SA Chart 1 Jahr
5-Tage-Chart
EQUASENS SA 5-Tage-Chart
RealtimeGeldBriefZeit
40,90041,00015:07
GlobeNewswire (Europe)
465 Leser
Artikel bewerten:
(2)

EQUASENS: Equasens: Acquisition of a majority stake in DIGIPHARMACIE

Finanznachrichten News

Villers-lès-Nancy, 2 January 2024 - 6:00 p.m. (CET)

PRESS RELEASE

Acquisition of a majority stake in DIGIPHARMACIE,
An expert in digital and invoice management solutions for pharmacies

  • With this acquisition, Equasens Group:
    • Strengthens its offering of solutions for healthcare professionals and consolidates its position as a leading European provider of digital healthcare solutions.
    • Addresses the growing demand for digital invoicing solutions following the introduction of new obligations in France.
    • Gives pharmacists more time to devote to their patients in a context characterised by increasing difficulties in recruitment in France and Europe.

Equasens Group, a leading healthcare software publisher (Euronext Paris - Compartment A - ISIN: FR 0012882389 - Ticker EQS) today announces its acquisition of a 70% majority stake in the start-up DIGIPHARMACIE.

An innovative and profitable young company

Based in the Paris region and created in 2019, DIGIPHARMACIE is a pure player in digital invoicing solutions for pharmacies. As a provider of SaaS (Software as a Service) solutions for pharmacies, the DNA of this French start-up, led by Yonathan BLAJMAN, David CHALOM and Jonathan FITOUSSI, includes a significant technological component by enabling pharmacies to automatically collect, centralise and store supplier invoices and using artificial intelligence to digitise and structure data flows to the applications used by their external accountants. DIGIPHARMACIE's ready-to-deploy offering also addresses the needs of the pharmaceutical industry. As such, it already complies with the obligation requiring all invoices to be sent and received electronically by 1 September 2026.

With an installed base of already nearly 70% of French pharmacies (13,000 pharmacy customers), nearly 300 accounting firms, including major national groups, and an agreement with nearly 80% of pharmacy groups, DIGIPHARMACIE processes more than 1 million invoices each month on its platform.

Reflecting its achievements, in 2023 DIGIPHARMACIE was a recipient of the Prix de l'Innovation PharmagoraPlus (PharmagoraPlus Innovation Award).

"This acquisition of a majority stake in Digipharmacie provides yet another confirmation of the Equasens Group's commitment to supporting innovative start-ups," commented Denis SUPPLISSON, Chief Executive Officer of Equasens. "DIGIPHARMACIE has been profitable since its creation in 2019 and has very quickly become the leader in its market. As a result of this acquisition, we are now able to offer pharmacists and their chartered accountants a complete and disruptive solution to meet their needs in the area of electronic invoicing."

"We are delighted to become a member of the Equasens Group, which will provide us with invaluable expertise and support our continued growth and development" stated Yonathan BLAJMAN, pharmacist and co-founder of DIGIPHARMACIE, adding that "As a result of this alliance, we are now able to offer our customers a more comprehensive and innovative range of services, and address the growing need for more of effective and efficient digital solutions in the healthcare ecosystem."

Electronic invoicing: an indispensable new development for healthcare professionals in France.

Equasens' acquisition of a majority stake in DIGIPHARMACIE represents an important turning point in the digital transformation of the healthcare sector. On this basis, the two companies are now able to offer a comprehensive solution that addresses the new requirement for all invoices to be received in electronic form by 1 September 2026.

  • Time savings and improved back office efficiency: the DIGIPHARMACIE solution simplifies and automates invoice management processes, as well handling electronic bills of exchange. By generating time-savings of approximately 10 hours per month (DIGIPHARMACIE data), healthcare professionals are able to focus their attention on be more strategic, added-value for the benefit of patients.
  • Reduce costs and improve carbon footprint: e-invoicing reduces printing, eliminates paper archiving and simplifies invoice processing.
  • Improved security: digitising invoices through DIGIPHARMACIE means that data is stored securely on highly secure online servers.
  • Improved data quality and traceability: the DIGIPHARMACIE solution makes it possible to monitor the status of invoices in real time and guarantee the quality of the data, facilitating their processing by the management software system used by healthcare professionals and their accountants.
  • A simplified user experience with a mobile app that allows pharmacists to:
    • integrate invoices through the photo function,
    • integrate expense reports,
    • offering a vault for storing important and/or sensitive documents.

Through this collaboration, the two companies will be able to extend the range of functions available to pharmacists to further simplify and secure their administrative workload. It will also make it possible to extend this approach to other healthcare professionals.

About Group Equasens

Founded more than 35 years ago, Equasens Group, which now has more than 1400 employees in Europe, is the leading publisher of software solutions for the healthcare industry in terms of the diversity of its business applications and market share.

Equasens Group's specialised business applications facilitate the day-to-day work of healthcare professionals and their teams, working in private practice, collaborative medical structures or healthcare establishments. The Group also provides comprehensive support to healthcare professionals in the transformation of their profession by developing electronic equipment, digital solutions and healthcare robotics, as well as financing and training adapted to their specific needs.

And reflecting the spirit of its tagline "more technology for more humanity", the Group is a leading provider of interoperability solutions that improve coordination between healthcare professionals, their communications and data exchange resulting in better patient care and a more efficient healthcare system.

Listed on Euronext Paris - Compartment A

Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable
Included in the Euronext Tech Leaders segment and the European Rising Tech label

Eligible for the Deferred Settlement Service ("Service à Réglement Différé" - SRD) and equity savings accounts invested in small and mid caps (PEA-PME).
ISIN: FR 0012882389 - Ticker Code: EQS

Get all the news about the Equasens Group www.equasens.com and on LinkedIn

CONTACTS

Analyst and Investor Relations:
Chief Administrative and Financial Officer: Frédérique SCHMIDT
Tel.: +33 (0)3 83 15 90 67 - frederique.schmidt@equasens.com

Financial Press:
FIN'EXTENSO - Isabelle APRILE

Tel.: +33 (0)6 17 38 61 78 - i.aprile@finextenso.fr


© 2024 GlobeNewswire (Europe)
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.